scholarly journals P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients

2017 ◽  
Vol 12 (1) ◽  
pp. S1235-S1236
Author(s):  
Tao Jiang ◽  
Shengxiang Ren ◽  
Caicun Zhou
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Effusion ◽  
Tki Resistance ◽  
Nsclc Patients ◽  
Egfr Tki

scholarly journals Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients

Oncotarget ◽  
2017 ◽  
Vol 8 (37) ◽  
pp. 62648-62657 ◽  
Author(s):  
Tao Jiang ◽  
Aiwu Li ◽  
Chunxia Su ◽  
Xuefei Li ◽  
Chao Zhao ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Effusion ◽  
Tki Resistance ◽  
Nsclc Patients ◽  
Egfr Tki

scholarly journals Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion

Medicine ◽  
2016 ◽  
Vol 95 (47) ◽  
pp. e5392 ◽  
Author(s):  
Nan Qi ◽  
Fang Li ◽  
Xiaosong Li ◽  
Huanrong Kang ◽  
Hui Zhao ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Treatment Effect ◽  
Malignant Pleural Effusion ◽  
Nsclc Patients

Association of plasma EGFR T790M ctDNA status with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8080-8080
Author(s):  
Di Zheng ◽  
Xin Ye ◽  
Meizhuo Zhang ◽  
Yun Sun ◽  
Jiying Wang ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Advanced Nsclc ◽  
Tki Resistance ◽  
Nsclc Patients ◽  
Egfr Tki ◽  
Egfr T790m

scholarly journals PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance

Oncotarget ◽  
2017 ◽  
Vol 8 (60) ◽  
pp. 101535-101544 ◽  
Author(s):  
Yan Zhang ◽  
Cheng Xiang ◽  
Yuling Wang ◽  
Yuanyuan Duan ◽  
Ci Liu ◽  
...  
Keyword(s):  
Promoter Methylation ◽  
Resistance Response ◽  
Tki Resistance ◽  
Nsclc Patients ◽  
Egfr Tki
Sign in / Sign up

Export Citation Format

Share Document